Navigation Links
Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment
Date:4/16/2008

ROCHESTER, Minn., April 16, 2008 /PRNewswire-USNewswire/ -- A new Mayo Clinic study found that regular physical exercise may help protect against mild cognitive impairment, a disorder of the brain that affects nerve cells involved in thinking abilities. This study will be presented at the American Academy of Neurology Annual Meeting in Chicago on April 16.

Individuals with mild cognitive impairment can function reasonably well in everyday activities, but often have difficulty remembering details of conversations, events and upcoming appointments. Most (but not all) patients with mild cognitive impairment develop a progressive decline in their thinking abilities over time. Alzheimer's disease is usually the underlying cause.

"While the benefits of exercise are well documented for improving overall health, this is one of the first studies to specifically look at whether it can help protect against the development of mild cognitive impairment," says Yonas Endale Geda, M.D., a Mayo Clinic neuropsychiatrist and the study's lead investigator.

As part of the ongoing Mayo Clinic Study of Aging, Dr. Geda and a team of Mayo Clinic researchers randomly identified 868 individuals 70 to 89 years old. Of those, 128 had mild cognitive impairment and 740 were cognitively normal. The team conducted surveys to gather data on the individuals' physical exercise between the ages of 50 and 65 and one year prior to the survey. They found that moderate physical exercise two to five times per week during the ages of 50 to 65 was associated with a reduced risk of mild cognitive impairment. However, the individual's exercise habits one year prior to the survey did not appear to be associated with a reduced risk.

According to Dr. Geda, these findings need to be replicated in a prospective cohort study. Additionally, the study did not address how physical exercise could protect against mild cognitive impairment.

"Regarding the mechanism of action of physical exercise and mild cognitive impairment, we speculate that either exercise induces chemicals that protect brain cells, or exercise is simply a marker for an overall healthy lifestyle, or there is some positive interaction among exercise, healthy lifestyle and intellectually stimulating activity," says Dr. Geda.

Dr. Geda and his team will continue to follow the study participants to examine if the case-control study finding will also hold true in further studies. Other members of the Mayo Clinic research team included Rosebud Roberts, M.B.Ch.B., David Knopman, M.D., Teresa Christianson, V. Shane Pankratz, Ph.D., Bradley Boeve, M.D., Eric Tangalos, M.D., Robert Ivnik, Ph.D., Walter Rocca, M.D., and Ronald Petersen, M.D., Ph.D.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
Breaking Medicine Technology:
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):